Elliot Israel, MD
Pulmonary Disease · Brookline, MANPI 1003891151
Payments from drug & device makers
Across 293 payments — averaging $4648.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$903K
- Sanofi US Services Inc.$178K
- GSK$56K
- Sanofi$47K
- Teva Pharmaceuticals USA, Inc.$46K
- Regeneron Healthcare Solutions, Inc.$34K
- plus $98K from 12 others
Across 25 payments — averaging $473.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$8K
- Amgen$2K
- Sanofi-aventis U.S. LLC$2K
What the payments were for
- Consulting fees$240,13182%
- Speaking & faculty fees$1220%
- Travel & lodging$48,16416%
- Food & beverage$4,4082%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 103 | $903,433 |
| Sanofi US Services Inc. | 23 | $177,691 |
| GSK | 35 | $56,149 |
| Sanofi | 19 | $46,771 |
| Teva Pharmaceuticals USA, Inc. | 15 | $46,499 |
| Regeneron Healthcare Solutions, Inc. | 33 | $33,818 |
| Amgen | 10 | $21,149 |
| Merck | 13 | $18,366 |
| Astrazeneca UK Limited | 13 | $17,998 |
| Astrazeneca AB | 4 | $12,000 |
| Novartis | 9 | $10,867 |
| Regeneron | 9 | $6,605 |
| Chiesi USA, Inc. | 2 | $3,500 |
| Circassia Inc. | 1 | $3,250 |
| Sanofi-aventis U.S. LLC | 1 | $2,264 |
| Pfizer | 1 | $1,400 |
| Medical Graphics Corporation | 1 | $161 |
| Genentech USA, Inc. | 1 | $137 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,362,057 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 13 | $1,031 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Brookline
- Sarah GrantBrookline$678K
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Ehab BillatosWinchester$2.7M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Curtis MelloNorth Dartmouth$1.9M
- Gary HunninghakeBoston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.